The simple solution to this is to make them run a superiority trial. If the drug is clinically or economically superior, they get their patent protection. If it is non-inferior, they don't.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC